Business
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Jon Congleton, a seasoned biopharmaceutical executive with nearly 40 years of experience spanning drug development, commercialization and corporate leadership, to its Board of Directors, effective March 27, 2026.
About this update from Teva Pharmaceutical Industries Limited
[{"type":"text","content":"– Nearly 40-Year Biopharmaceutical Professional with Deep CNS and Commercial Leadership Experience in Multiple Sclerosis –","length":122,"tagName":"p","attribs":{}},{"type":"text","content":"– Served on Original Team Responsible for the Launch of Copaxone® in the United States –","length":88,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, March 31, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Jon Congleton, a seasoned biopharmaceutical executive with nearly 40 years of experience spanning drug development, commercialization and corporate leadership, to its Board of Directors, effective March 27, 2026.","length":439,"tagName":"p"},{"type":"text","content":"Mr. Congleton has a strong track record of building and leading biopharmaceutical organizations and advancing innovative therapies. During his career, he has worked across cardiovascular, gastrointestinal, and central nervous system (CNS) organizations, with a focus on delivering solutions for patients and their caregivers. He played a key role in the U.S. launch of Teva Pharmaceuticals Industries Ltd.'s Copaxone®, a subcutaneous injection treatment for relapsing forms of multiple sclerosis (MS), and led the U.S. operations when it became the number one prescribed MS treatment.","length":588,"tagName":"p"},{"type":"text","content":"Mr. Congleton currently serves as Chief Executive Officer (CEO) and member of the Board of Directors of Mineralys Therapeutics, Inc., focused on aldosterone-driven cardiorenal conditions. As CEO, he guided the company from an early-stage private entity to the publicly traded, pre-commercial biotechnology firm it is today. Previously, he served as CEO and Board member of both CNS company Impel NeuroPharma, Inc. and cystic fibrosis company Nivalis Therapeutics, Inc.. Earlier, Mr. Congleton held several senior leadership roles at Teva Pharmaceuticals, eventually leading its United States and Canadian neuroscience businesses and global CNS franchise.","length":659,"tagName":"p"},{"type":"text","content":""MS remains a devastating disease for the patients and their families. Jon's deep CNS expertise and proven track record in late-stage drug development and comme...